Details of the Drug | DrugMAP

General Information of Drug (ID: DMYYLC0)

Drug Name

DP-001

Indication

Disease Entry	ICD 11	Status	REF
Osteoporosis	FB83.0	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C27H44O3
Canonical SMILES: CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(=C)C(C3)O)O)C
InChI: 1S/C27H44O3/c1-18(8-6-14-26(3,4)30)22-12-13-23-21(9-7-15-27(22,23)5)11-10-20-16-24(28)19(2)25(29)17-20/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b21-11+/t18-,22?,23-,24+,25+,27+/m0/s1
InChIKey: UHMPCVGLSKFXHR-NFZXMVPNSA-N

Cross-matching ID

PubChem CID: 11366080
CAS Number: 213250-70-5
TTD ID: D0N5XI

References

1	ClinicalTrials.gov (NCT01653379) A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism. U.S. National Institutes of Health.